{"doi":"10.1016/j.annonc.2022.07.1676","title":"1583P Evaluation of immune checkpoint inhibitors rechallenge after immune-related adverse events in patients with cancer","abstract":null,"journal":"Annals of Oncology","year":2022,"id":673176,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1499377,"name":"R. Li","orcid":"0009-0002-9359-6888","position":1,"is_corresponding":false},{"id":1758822,"name":"F. Zhao","orcid":null,"position":2,"is_corresponding":false},{"id":1484122,"name":"X. Wen","orcid":"0000-0003-0599-7308","position":3,"is_corresponding":false},{"id":1758824,"name":"Y-K. Wang","orcid":null,"position":4,"is_corresponding":false},{"id":1758826,"name":"R-X. Lv","orcid":null,"position":5,"is_corresponding":false},{"id":1758821,"name":"X-R. Tang","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"1583P Evaluation of immune checkpoint inhibitors rechallenge after immune-related adverse events in patients with cancer","abstract":null,"is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19162232","pmcid":null,"openalex_id":"https://openalex.org/W4295836826","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.15225292,"influential_citations":0,"citation_trend":[],"oa_status":"bronze","license":"http://www.elsevier.com/open-access/userlicense/1.0/","oa_locations":[{"url":"http://www.annalsofoncology.org/article/S092375342203527X/pdf","host_type":"journal"},{"url":"http://www.annalsofoncology.org/article/S092375342203527X/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S092375342203527X?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S092375342203527X?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.annonc.2022.07.1676","host_type":"journal"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","Advanced Breast Cancer Therapies","Colorectal Cancer Treatments and Studies"],"mesh_terms":[],"keywords":["Medicine","Adverse effect","Regimen","Adverse Event Reporting System","Internal medicine","Immune system","Oncology","Immunology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-16T12:37:09.648900Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}